Infections

All Conditions

Symptoms and General Pathology

Blood and Lymph Conditions

Immune System Diseases

Communicable Diseases

Epstein-Barr Virus Infections

Virus Diseases

Infectious Mononucleosis

Disease Attributes

Herpesviridae Infections

DNA Virus Infections

Tumor Virus Infections

Leukocyte Disorders

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Anti-Infective Agents

All Drugs and Chemicals

Antiviral Agents

Valomaciclovir 2 grams orally twice daily for 21 days

placebo 2 tablets twice daily for 21 days

4 grams orally of valomaciclovir (2 grams BID) for 21 days.

Valomaciclovir

Placebo tablets orally twice daily for 21 days.

placebo

Henry H Balfour, MD

This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis documented to be caused by primary EBV infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical diagnosis of primary infectious mononucleosis will be screened and those with laboratory-confirmed primary EBV infection will be enrolled.

Subjects will be seen 2 times a week for 3 weeks and then weekly for 3 weeks. Clinical findings, clinical lab tests, EBV viral loads, and EBV antibody titers will be obtained at each clinic visit.

Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection

Randomized, Placebo-Controlled, Double-Blind Study to Assess Clinical and Antiviral Activity of Valomaciclovir (EPB 348) in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection (Mono 6)

All subjects had confirmed cases of EB and will be assessed for Improvement of clinical symptoms (ie: tiredness, nausea etc)and reduction in viral burden from baseline

Assessing adverse events in participants to see if this drug causes more or less side effects

Epiphany Biosciences

University of Minnesota

Valomaciclovir 2 grams orally twice daily for 21 days

Valomaciclovir : 4 grams orally of valomaciclovir (2 grams BID) for 21 days.

placebo 2 tablets twice daily for 21 days

placebo : Placebo tablets orally twice daily for 21 days.

Placebo

Total

<=18 years

Between 18 and 65 years

>=65 years

Age, Customized

Sex: Female, Male

United States

Region of Enrollment

Hank Balfour MD

Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline

Valomaciclovir 2 grams orally twice daily for 21 days

Valomaciclovir: 4 grams orally of valomaciclovir (2 grams BID) for 21 days.

placebo 2 tablets twice daily for 21 days

placebo: Placebo tablets orally twice daily for 21 days.

Spots Global Cancer Trial Database for mono

Every month we try and update this database with for mono cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mono

Every month we try and update this database with for mono cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mono cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.